Weight-loss drugs such as semaglutide and tirzepatide have created a growing global market, attracting attention from patients, doctors, and investors alike, while a recent study published in JAMA Surgery has examined how bariatric surgery compares in terms of weight loss and long-term costs.

The research, led by Tyson S. Barrett, of Highmark Health in the United States, analysed the health records of 30,458 patients from the Highmark Health insurance claims database and the Allegheny Health Network. It compared outcomes for patients with class II and III obesity who underwent metabolic bariatric surgery either sleeve gastrectomy or gastric bypass, with those who received glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of drugs that includes semaglutide and tirzepatide. Ad

See Full Page